Invesaro

Stocks Health care YARW

NASDAQ · Health care

Yarrow Bioscience, Inc. (YARW)

Yarrow Bioscience, Inc. reported revenue of $570K in fiscal 2025, up 13.8% from a year earlier. It posted a net loss of $26.5M. In fiscal 2025 capital spending exceeded operating cash flow by $33.1M. At June 30, 2026 it held $22.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.

Price
$25.54
-2.03% on the day · September 25, 2026
52-week range $16.00 to $46.95
Market cap
$68.2M
Revenue (FY2025)
$570K
+13.8% year on year
Net margin
-4,646.1%

What Yarrow Bioscience, Inc. does

Yarrow Bioscience, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker YARW.

Revenue and profit by year

Revenue
FY18: $10.6M $10.6M FY18FY19: $443K $443K FY19FY20: $21M $21M FY20FY21: $931K $931K FY21FY22: $477K $477K FY22FY23: $424K $424K FY23FY24: $501K $501K FY24FY25: $570K $570K FY25
Net income
FY18: -$74.2M -$74.2M FY18FY19: -$95.2M -$95.2M FY19FY20: -$255.6M -$255.6M FY20FY21: -$73.3M -$73.3M FY21FY22: -$23.2M -$23.2M FY22FY23: -$28.5M -$28.5M FY23FY24: -$39.8M -$39.8M FY24FY25: -$26.5M -$26.5M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$570K-$29.7M-$26.5M-$0.62-$33.1M
2024$501K-$43.6M-$39.8M-$0.93-$34.1M
2023$424K-$29.3M-$28.5M-$2.78-$25.3M
2022$477K-$34.3M-$23.2M-$7.28n/a
2021$931K-$38.9M-$73.3M-$25.64-$56.4M
2020$21M-$252.5M-$255.6M$7.88-$137.2M

Latest SEC filings

What Yarrow Bioscience, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 17, 2026
  2. September 14, 2026
  3. September 11, 2026
  4. September 11, 2026
  5. September 10, 2026
  6. August 14, 2026
  7. August 14, 2026
  8. August 14, 2026
  9. August 13, 2026
  10. August 13, 2026
    Quarterly report 10-Q · period to June 30, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 30, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about YARW

What does Yarrow Bioscience, Inc. do?

Yarrow Bioscience, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker YARW.

Is Yarrow Bioscience, Inc. profitable?

No. In fiscal 2025 it reported a net loss of $26.5M on revenue of $570K.

How much revenue does Yarrow Bioscience, Inc. make?

In fiscal 2025 Yarrow Bioscience, Inc. reported revenue of $570K. That is 13.8% more than a year earlier.

When did Yarrow Bioscience, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from September 17, 2026.

Similar companies

Follow YARW

Get an email when Yarrow Bioscience, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow YARW: get an email when it files

Where the numbers come from

Financial figures are the values Yarrow Bioscience, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.